Astrazeneca Stock News

AstraZeneca announced its first dividend increase in a decade and forecast higher sales for 2022.

Pascal Soriot, Chief Executive Officer, commenting on the results said: AstraZeneca continued on its strong growth trajectory in 2021, with industry-leading R&D productivity, five of our medicines crossing new blockbuster thresholds, and the acquisition and integration of Alexion. We also delivered on our promise of broad and equitable access to our COVID-19 vaccine with 2.5 billion doses released for supply around the world, and we made good progress on reducing our greenhouse gas emi Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=285116

The Anglo-Swedish pharma giant posted a net loss of $347 million for the last quarter of the year compared with a net profit of $1.01 billion the year prior

AstraZeneca recorded a $4 billion increase in revenue Thursday as the company begins to turn a profit from its coronavirus vaccine.The drug company saw full-year revenues of $37.4 billion in 2021, a 38 percent incr…

Shares of AstraZeneca plc (NASDAQ: AZN) are up 3.5% this morning on a significant YoY increase in Q4 revenue. Charges related to the Alexion acquisition, however, pushed it into a quarterly loss.

Drugmaker’s total revenues increased by 41% last year with help from $4bn Covid jab income

AstraZeneca helped nudge U.K. blue chips higher as the pharma giant showed how its acquisition of Alexion will push profits higher.

The drugmaker forecasts a high teens percentage increase in total revenue in 2022

AstraZeneca (NASDAQ: AZN ) reported its Q4 earnings results on Thursday, February 10, 2022 at 02:15 AM. Here''s what investors need to know about the announcement. Check out this: Insiders Buy Over $43M Of 4 Stocks Earnings AstraZeneca beat estimated earnings by … Full story available on Benzinga.com

British–Swedish multinational pharmaceutical company AstraZeneca on Thursday forecast higher sales in 2022 after posting a better-than-expected fourth-quarter profit. But the biotechnology company warned that it expects revenues to decline as sales of its COVID-19 products drop, and that the gross profit margins from those products would be lower than the company average. The drugmaker recorded full-year revenues […]

Futures Paralyzed Ahead Of Critical CPI Print US index futures are unchanged from Wednesday''s close after some rangebound trades in another illiquid, overnight session, as traders were paralyzed and unwilling to commit capital ahead of today''s critical CPI print which consensus expects to come in at 7.2% YoY headline and 5.9% core, but which may well surprise to the downside (we explained why yesterday ) after beating expectations on 8 of the past 10 occasions. A miss will likely send yields lower and risk sharply higher, especially when considering that the BLS will revise its CPI basket weightings and seasonal adjustments today. On the other hand, an upside surprise could spur additional pricing for a 50bp rate hike at the March meeting, currently priced in the swaps market at around 28%, and as such the 830am CPI print will shape views on how aggressively the Federal Reserve will tighten monetary policy in coming weeks. Contracts on the S&P 500 were flat, and the Nasdaq drifted lower after a broad Wall Street rally on Tuesday, US Treasury yields were lower as was the dollar while bond yields in most of Europe ticked higher, as did bitcoin which briefly rose above $45,000 . “This inflation data will provide investors with more clues on how aggressive the Fed could be at its next policy meeting, sparking volatility in both bond and stock markets,” said Pierre Veyret, a technical analyst at ActivTrades.

AstraZeneca raised its annual dividend for the first time in a decade on Thursday, February 10, and forecast higher sales for 2022 as new drugs against cancer, kidney disease, and rare conditions make up for a decline in COVID-19 products. Early data has shown a booster shot of the drugmakers widely-used COVID-19 vaccine and its antibody drug Evusheld both work against the Omicron coronavirus variant. But while the company forecasts sales of Evusheld to grow this year, it expects that will be more than outweighed by a decline in sales of the vaccine amid growing competition. AstraZeneca has started earning a modest profit on the vaccine, which was initially sold at-cost under a deal with its developers at Oxford University. But the company said it would continue to sell it to low-income nations on a non-profit basis. While sales of COVID-19 products are expected to decline by a low-to-mid 20s percentage this year, the London-listed company forecast overall revenues to rise by a high teens percentage, with core earnings up by a mid-to-high 20s percentage.

AstraZeneca Earnings, Revenue Beat in Q4

AstraZeneca Plc''s (NASDAQ: AZN ) total revenue jumped 63% Y/Y to $12.01 billion in Q4 FY21 on a constant-currency basis, beating the consensus of $10.96 billion. Core earnings per share (EPS) came in at $1.67, topping estimates of $0.73. In Q4, sales of the COVID-19 vaccine, Vaxzevria, were $1.76 billion, the best-selling product for AstraZeneca, lung cancer drug Tagrisso, racked up $1.3 billion in revenues. The Company posted a Q4 FY21 net loss of $(346) million, despite Full story available on Benzinga.com